V10
A focused RF-only platform, the V10 delivers fractional and non-fractional radiofrequency for safe, effective full-body rejuvenation—ideal for skin tightening, contouring, and resurfacing.
GET IN TOUCH
The V-Series is a modular platform of energy based devices designed for non-invasive aesthetic treatments. Combining technologies such as radiofrequency, IPL, and Nd:YAG laser, it offers customisable solutions suitable for a wide range of practitioners: from dermatologists, cosmetic and plastic surgeons, to dentists, and spa professionals.
Four Powerful Technologies
V20
Combines radiofrequency and IPL in one versatile system, offering flexible combination treatments via multiple handpieces and built-in protocols for facial and body indications.
REQUEST A DEMO
V30
The most advanced platform, integrating RF, IPL, and 1064 nm Nd:YAG laser technologies. Modular and upgradeable, the V30 enables clinicians to customise treatment configurations with precision and enhanced safety control.
SPEAK WITH OUR VIRTUAL ACCOUNT MANAGERS
V-Series regulations
- V-ST
- USA - for the temporary relief of minor muscle aches and pain, temporary relief of muscle spasm, and temporary improvement of local blood circulation
- EU - skin tightening
- V-FORM
- USA - relief of minor muscle aches and pain, relief of muscle spasm, temporary improvement of local blood circulation and temporary reduction in the appearance of cellulite
- EU - temporarily reduction of cellulite and Body contouring via temporary circumferences reduction
- V-FR
- USA - dermatological procedures requiring ablation and resurfacing of the skin
- EU - ablation and resurfacing of the skin
- V-VR
- USA - temporary relief of minor muscle aches and pain, temporary relief of muscle spasm, and temporary improvement of local blood circulation
- EU - electrocoagulation of soft tissues for the treatment of vulvovaginal laxity. The vulva area is referred to the labia majora
- V-IPL
- USA - Moderate inflammatory acne vulgaris. Benign pigmented epidermal lesions including dyschromia, hyperpigmentation, melasma, and ephelides (freckles). Cutaneous lesions including warts, scars and striae. Benign cutaneous vascular lesions including port wine stains, hemangiomas, facial, truncal and leg telangiectasias, rosacea, erythema of rosacea, angiomas and spider angiomas, poikiloderma of Civatte and venous malformations. Removal unwanted hair. It is also intended for permanent reduction in unwanted hair. Permanent hair reduction is defined as the long-term stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regimen.
- EU - Hair reduction, skin rejuvenation treatment of superficial small vascular and pigmented lesions and treatment of mild to moderate inflammatory acne
- V-Nd:YAG
- USA - Benign vascular lesions such as, but not limited to treatment of: port wine stains, hemangiomas, Warts, superficial and deep telangiectasias (venulectasias), reticular veins (0.1-4.0 mm dia.) of the leg, rosacea, venus lake, leg veins, spider veins, poikiloderma of civatte and angiomas. Benign cutaneous lesions, such as, but not limited to: warts, scars, striae and psoriasis. Benign pigmented lesions such as, but not limited to: lentigos (age spots), solar lentigos (sun spots), cafe-aulait macules, seborrheic keratosis, nevi and nevus of Ota, chloasma, verrucae, skin tags and keratosis. Pigmented lesions to reduce lesion size, for patients with lesions that would potentially benefit from aggressive treatment, and for patients with lesions that have not responded to other laser treatments. The non-ablative treatment of facial wrinkles, such as, but not limited to: periocular wrinkles and perioral wrinkles. Laser skin resurfacing procedures for the treatment of: acne scars and wrinkles. Reduction of red pigmentation in hypertrophic and keloid scars where vascularity is an integral part of the scar. Removal of unwanted hair. It is also intended for permanent reduction in unwanted hair. Permanent hair reduction is defined as the long-term stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regimen and treatment of pseudofolliculitis barbae (PFB).
- EU - hair reduction, treatment of vascular lesions and treatment of onychomycosis